UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 465

Sortiert nach

2-weekly versus 3-weekly docetaxel for prostate cancer

The lancet oncology, 2013-02, Vol.14 (2), p.98-99

2013

Link zum Volltext

Verfügbarkeit prüfen

A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of penile cancer

Urologic oncology, 2021-09, Vol.39 (9), p.569-576

2021

Link zum Volltext

Verfügbarkeit prüfen

A 25-year review of advances in testicular cancer: Perspectives on evaluation, treatment, and future directions/challenges

Urologic oncology, 2021-09, Vol.39 (9), p.561-568

2021

Link zum Volltext

Verfügbarkeit prüfen

952 ANTI-PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)-BASED RADIOIMMUNOTHERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A DECADE OF EXPERIENCE WITH RADIOLABELED (RL)-J591

The Journal of urology, 2012-04, Vol.187 (4), p.e387-e388

2012

Link zum Volltext

Verfügbarkeit prüfen

99m Tc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer

Journal of Nuclear Medicine, 2014-11, Vol.55 (11), p.1791-1798

2014

Link zum Volltext

Verfügbarkeit prüfen

99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer

The Journal of nuclear medicine (1978), 2014-11, Vol.55 (11), p.1791-1798

2014

Link zum Volltext

Verfügbarkeit prüfen

Abiraterone and Increased Survival in Metastatic Prostate Cancer

The New England journal of medicine, 2011-05, Vol.364 (21), p.1995-2005

2011

Link zum Volltext

Verfügbarkeit prüfen

Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer

Asian journal of andrology, 2011-11, Vol.13 (6), p.785-786

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1264: CTC-based biomarker analysis and correlation with clinical response to PSMA-TRT in mCRPC

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1264-1264

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 134: Immunogenomic landscape of neuroendocrine prostate cancer (NEPC)

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.134-134

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1749: Stability of copy-number profiles defines two molecular subtypes during urothelial carcinoma’s evolution

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1749-1749

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1774: External beam radiation therapy and androgen deprivation therapy increase PSMA expression in prostate cancer

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1774-1774

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1905: Possible cancer stem cells: Folate hydrolase-1 is expressed in a subset of Oct4-positive melanoma cells

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1905-1905

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1947: Rovalpituzumab tesirine as a therapeutic agent for neuroendocrine prostate cancer

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1947-1947

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2125: ERG and AR-v7 involvement in taxane resistance of metastatic castration-resistant prostate cancers

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.2125-2125

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2143: Cancer of unknown Primary (CUP): Beyond the identification of the site of origin by an integrative genomic approach

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.2143-2143

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 2736: A digital droplet PCR assay for the quantitation of androgen receptor and splice variant expression in CTCs from metastatic castration resistant prostate cancer patients

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.2736-2736

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract 296: Characterization of prostate cancer circulating tumor cells using E-selectin coated-microtubes

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.296-296

2011

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3437: Whole genome and transcriptome sequencing of a pan cancer cohort unearths novel therapeutic avenues

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.3437-3437

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3492: Using CTCs to interrogate mechanisms of taxane resistance in the prospective TAXYNERGY clinical trial in prostate cancer

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3492-3492

2013

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3634: Molecular determinants of taxane activity using CTCs from CRPC patients

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3634-3634

2012

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3880: Next generation sequencing for discovery of somatic mutations and clonal relationships in platinum-resistant metastatic urothelial cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3880-3880

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3971: Non-invasive assessment of prostate-specific membrane antigen (PSMA) expression as a prognostic marker in men with metastatic castration-resistant prostate cancer (mCRPC)

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3971-3971

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract 426: Variant allele frequency changes and treatment responses in advanced prostate cancer

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.426-426

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 465

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(453)
Mit Volltextzugriff
(412)

Publikationsform

Artikel
(458)
Buchkapitel
(3)
Berichte
(3)
Texte
(1)

Sprache

Englisch
(465)
Japanisch
(28)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

2-weekly versus 3-weekly docetaxel for prostate cancer

A 25-year perspective on advances in an understanding of the biology, evaluation, treatment and future directions/challenges of penile cancer

A 25-year review of advances in testicular cancer: Perspectives on evaluation, treatment, and future directions/challenges

952 ANTI-PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)-BASED RADIOIMMUNOTHERAPY FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): A DECADE OF EXPERIENCE WITH RADIOLABELED (RL)-J591

99m Tc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer

99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Abiraterone and Increased Survival in Metastatic Prostate Cancer

Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer

Abstract 1264: CTC-based biomarker analysis and correlation with clinical response to PSMA-TRT in mCRPC

Abstract 134: Immunogenomic landscape of neuroendocrine prostate cancer (NEPC)

Abstract 1749: Stability of copy-number profiles defines two molecular subtypes during urothelial carcinoma’s evolution

Abstract 1774: External beam radiation therapy and androgen deprivation therapy increase PSMA expression in prostate cancer

Abstract 1905: Possible cancer stem cells: Folate hydrolase-1 is expressed in a subset of Oct4-positive melanoma cells

Abstract 1947: Rovalpituzumab tesirine as a therapeutic agent for neuroendocrine prostate cancer

Abstract 2125: ERG and AR-v7 involvement in taxane resistance of metastatic castration-resistant prostate cancers

Abstract 2143: Cancer of unknown Primary (CUP): Beyond the identification of the site of origin by an integrative genomic approach

Abstract 2736: A digital droplet PCR assay for the quantitation of androgen receptor and splice variant expression in CTCs from metastatic castration resistant prostate cancer patients

Abstract 296: Characterization of prostate cancer circulating tumor cells using E-selectin coated-microtubes

Abstract 3437: Whole genome and transcriptome sequencing of a pan cancer cohort unearths novel therapeutic avenues

Abstract 3492: Using CTCs to interrogate mechanisms of taxane resistance in the prospective TAXYNERGY clinical trial in prostate cancer

Abstract 3634: Molecular determinants of taxane activity using CTCs from CRPC patients

Abstract 3880: Next generation sequencing for discovery of somatic mutations and clonal relationships in platinum-resistant metastatic urothelial cancer

Abstract 3971: Non-invasive assessment of prostate-specific membrane antigen (PSMA) expression as a prognostic marker in men with metastatic castration-resistant prostate cancer (mCRPC)

Abstract 426: Variant allele frequency changes and treatment responses in advanced prostate cancer

Suchergebnisse filtern